An aspirin a day keeps colorectal cancer away

May 10, 2007

Long term use of 300mg or more of aspirin a day for five years can prevent colorectal cancer, conclude authors of a study published in this week's special gastroenterology edition of The Lancet.

But the authors of the study and an accompanying comment stress that the potential risks of long term aspirin use at this dose and the availability of alternative prevention strategies mean that widespread use of aspirin for cancer prevention cannot be recommended in the general population.

However, the benefits are likely to outweigh the risks in individuals at increased risk of colon cancer. The findings are also likely to influence the choice of antiplatelet drug in patients who require long-term treatment because of vascular disease.

The study was conducted by Professor Peter Rothwell, University Department of Clinical Neurology, Radcliffe Infirmary, Oxford, UK and colleagues. In collaboration with the original investigators (Sir Richard Doll, Sir Richard Peto and Charles Warlow), they determined the delayed effect of aspirin by following-up patients from two large randomised trials of aspirin performed in the late 1970s and early 80s - the British Doctors' Aspirin Trial and the UK-TIA Aspirin Trial.

The researchers were particularly interested in long term follow-up due to the likely time delay in any effect of aspirin on colorectal cancer. Adenomas (the pre-cancerous growths that aspirin is thought to reduce) take at least 10 years to develop into cancers. The study showed that use of Aspirin for five years reduced the subsequent incidence of colorectal cancer by 37% overall, and by 74% during the period 10-15 years after treatment was started.

In an accompanying analysis of observational studies, the risk of colorectal cancer also appeared to be reduced by between 50-70% in patients taking medium-high doses of aspirin for 10 years or more. This analysis also showed that the effects of aspirin were consistent regardless of age, sex, race or country of origin of patients studied (all of which affect the general rate of colorectal cancer) and that the effect was also seen in individuals with a family history of colorectal cancer in a first degree family relative (which increases lifetime risk of an individual acquiring the disease by two to four times).

The authors conclude: "Use of 300mg or more of aspirin a day for about five years is effective in primary prevention of colorectal cancer, with a latency of about 10 years, which is consistent with findings from observational studies.

"Long-term follow up is required from other randomised trials to establish the effects of lower or less frequent doses of aspirin."

In an accompanying comment, Dr Andrew Chan, Gastrointestinal Unit, Massachusetts General Hospital, Boston, USA, says: "Rothwell and colleagues' results, when viewed in the context of the preponderance of laboratory studies, epidemiological data, and adenoma recurrence trials, do provide convincing evidence that aspirin, at biologically relevant doses, can reduce the incidence of colorectal cancer.

"However, with the concerns about the potential risks of long-term aspirin use and the availability of alternative prevention strategies (e.g. screening), these findings are not sufficient to warrant a recommendation for the general population to use aspirin for cancer prevention."
-end-


Lancet

Related Colorectal Cancer Articles from Brightsurf:

Colorectal cancer treatment: the winning combinations
Chemotherapy has distressing side effects for patients and increases the risk of developing resistance to the treatment.

A new model to predict survival in colorectal cancer
This signature could be useful in clinical practice, especially for colorectal cancer diagnosis and therapy.

Roadmap to reducing colorectal cancer deaths
The American Gastroenterological Association has outlined a strategy to increase the number of people screened via tests that are more convenient, accurate and less expensive and tailored to people's individual cancer risks.

Study provides new insight on colorectal cancer growth
A new study by researchers at the University of Kentucky identifies a novel function of the enzyme spermine synthase to facilitate colorectal cancer growth.

Researchers ID target for colorectal cancer immunotherapy
Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center have identified a target for colorectal cancer immunotherapy.

Colorectal cancer partner-in-crime identified
A protein that helps colorectal cancer cells spread to other parts of the body could be an effective treatment target.

Cancer cell reversion may offer a new approach to colorectal cancer treatment
A novel approach to reverse the progression of healthy cells to malignant ones may offer a more effective way to eradicate colorectal cancer cells with far fewer side effects, according to a KAIST research team based in South Korea.

A novel pathway to target colorectal cancer
Survival rates for patients with late-stage colorectal cancer are dismal, and new therapeutic strategies are needed to improve outcomes.

Colorectal cancer rates in Canada
The incidence of colorectal cancer among younger adults increased in recent years in this analysis of data from Canadian national cancer registries that included about 688,000 new colorectal cancers diagnosed over more than 40 years.

Cancer drugs promote stem cell properties of colorectal cancer
Scientists from the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and the Mannheim University Medical Center have now discovered that a certain group of cancer drugs (MEK Inhibitors) activates the cancer-promoting Wnt signalling pathway in colorectal cancer cells.

Read More: Colorectal Cancer News and Colorectal Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.